Tissue inhibitor of the metalloproteinases-3 gene polymorphisms and carotid plaque susceptibility in the Han Chinese population

References

• Lu C. Stroke in China - past, present and future. Rinsho Shinkeigaku. 2010;50(11):827.
   PubMedGoogle Scholar
• Jander S, Sitzer M, Wendt A, et al. Expression of tissue factor in high grade carotid artery stenosis. Association with plaque destabilization. Stroke. 2001;32:850–854.
   PubMed Web of Science ®Google Scholar
• Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke. 2005;36(2):253–257.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251–262.
   PubMed Web of Science ®Google Scholar
• Peng J, Xin H, Han P, et al. Expression and regulative function of tissue inhibitor of metalloproteinase 3 in the goat ovary and its role in cultured granulosa cells. Mol Cell Endocrinol. 2015;412:104–115.
   PubMed Web of Science ®Google Scholar
• Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91(11):2844–2850.
   PubMed Web of Science ®Google Scholar
• Noji Y, Kajinami K, Kawashiri M-A, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39(5):380–384.
   PubMed Web of Science ®Google Scholar
• Sapienza P, di Marzo L, Borrelli V, et al. Metalloproteinases and their inhibitors are markers of plaque instability. Surgery. 2005;137(3):355–363.
   PubMed Web of Science ®Google Scholar
• Wen-Qi Ma, Qing-Rong Q, Yu Z, et al. Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(49):e5593.
   PubMed Web of Science ®Google Scholar
• Kinga B, Jacek K, Andrzej K, et al. MatrixMetalloproteinase-9(MMP-9) gene polymorphism in stroke patients. Neuromol Med. 2015;17(4):385–390.
   PubMed Web of Science ®Google Scholar
• Pleskovič A, Letonja MŠ, Vujkovac AC, et al. Matrix metalloproteinase-3 gene polymorphism (rs3025058) affects markers atherosclerosis in type 2 diabetes mellitus. Vasa. 2017;19:1–7.
   Google Scholar
• Rauch I, Iglseder B, Paulweber B, et al. MMP-9 haplotypes and carotid artery atherosclerosis: an association study introducing a novel multicolour multiplex Real Time PCR protocol. Eur J Clin Invest. 2008;38(1):24–33.
   PubMed Web of Science ®Google Scholar
• Djuric T, Živković M, Radak D, et al. Association of MMP-3 5A/6A gene polymorphism with susceptibility to carotid atherosclerosis. Clin Biochem. 2008;41(16–17):1326–1329.
   PubMed Web of Science ®Google Scholar
• Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008;29:258–289.
   PubMed Web of Science ®Google Scholar
• Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development. 2012;139:3693–3709.
   PubMed Web of Science ®Google Scholar
• Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Gene Dev. 2003;17(1):7–30.
   PubMed Web of Science ®Google Scholar
• Fata JE, Leco KJ, Voura EB, et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest. 2001;108(6):831–841.
   PubMed Web of Science ®Google Scholar
• Mohammed FF, Smookler DS, Taylor SEM, et al. Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36(9):969–977.
   PubMed Web of Science ®Google Scholar
• Denhardt DT, Feng B, Edwards DR, et al. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 1993;59(3):329–341.
   PubMed Web of Science ®Google Scholar
• Jackson HW, Hojilla CV, Weiss A, et al. Timp3 deficient mice show resistance to developing breast Cancer. Plos One. 2015;10(3):1–14.
   Web of Science ®Google Scholar
• Armstrong C, Abilleira S, Sitzer M, et al. Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke. 2007;38(11):2895–2899.
   PubMed Web of Science ®Google Scholar
• Cardellini M, Menghini R, Martelli E, et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes. 2009;58(10):2396–2401.
   PubMed Web of Science ®Google Scholar
• Moore L. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev. 2012;17(4–5):693.
   PubMed Web of Science ®Google Scholar
• Han SW, Kim SH, Lee JY, et al. A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol. 2007;57(2):96–102.
   PubMed Web of Science ®Google Scholar
• Djuric T, Živković M, Radak D, et al. Association of MMP-3 5A/6A gene polymorphism with susceptibility to carotid atherosclerosis. Clin Biochem. 2008;41(16–17):1326–1329.
   PubMed Web of Science ®Google Scholar
• Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the Tromso study. Circulation. 2001;103(17):2171–2175.
   PubMed Web of Science ®Google Scholar
• Ye S, Humphries S, Henney A. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci. 1998;94(2):103–110.
   PubMed Web of Science ®Google Scholar
• Lendon CL, Davies MJ, Born GVR, et al. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991;87–90.
   PubMed Web of Science ®Google Scholar
• Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74(2):111–122.
   PubMed Web of Science ®Google Scholar
• Petrovic D. The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease. Cardiovasc Hematol Agents Med Chem. 2010;8(1):47–54.
   PubMedGoogle Scholar
• Merlo S, Starčević JN, Mankoč S, et al. Vascular endothelial growth factor gene polymorphism (rs2010963) and Its receptor, kinase insert domain-containing receptor gene polymorphism (rs2071559), and markers of carotid atherosclerosis in patients with type 2 diabetes mellitus. J Diabetes Res. 2016;2016:1482194.
   PubMedGoogle Scholar
• Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9(4):407–415.
   PubMed Web of Science ®Google Scholar
• Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7(4):425–429.
   PubMed Web of Science ®Google Scholar
• Beranek M, Kankova K, Muzik J. Identification of novel common polymorphisms in the promoter region of the TIMP-3 gene in Czech population. Mol Cell Probes. 2000;14(4):265–268.
   PubMed Web of Science ®Google Scholar
• Hill MR, Briggs L, Montaño MM, et al. Promoter variants in tissue inhibitor of metalloproteinase-3 (TIMP-3) protect against susceptibility in pigeon breeders’ disease. Thorax. 2004;59(7):586–590.
   PubMed Web of Science ®Google Scholar
• Lei H, Hemminki K, Altieri A, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat. 2007;103(1):61–69.
   PubMed Web of Science ®Google Scholar
• Su CW, Huang YW, Chen MK, et al. Polymorphisms and plasma levels of tissue inhibitor of Metalloproteinase-3: impact on genetic susceptibility and clinical outcome of oral Cancer. Medicine. 2015;94(46):2087–2092.
   Web of Science ®Google Scholar
• Langton KP, Barker MD, McKie N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation. J Biol Chem. 1998;273(27):16778–16781.
   PubMed Web of Science ®Google Scholar
• Yu WH, Yu S-SC, Meng Q, et al. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000;275(40):31226–31232.
   PubMed Web of Science ®Google Scholar
• English JL, Kassiri Z, Koskivirta I, et al. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem. 2006;281(15):10337–10346.
   PubMed Web of Science ®Google Scholar
• Casagrande V, Menghini R, Menini S, et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2012;32(1):74–81.
   PubMed Web of Science ®Google Scholar
• Darnton SJ, Hardie LJ, Muc RS, et al. TIMP3 gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer. 2005;115(3):351–358.
   PubMed Web of Science ®Google Scholar
• Beaudeux JL, Giral P, Bruckert E, et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med. 2004;42(2):121–131.
   PubMed Web of Science ®Google Scholar
• Fabunmi RP, Sukhova GK, Sugiyama S, et al. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells a potential protective mechanism in plaque stability. Circ Res. 1998;83(3):270–278.
   PubMed Web of Science ®Google Scholar
• Chaturvedi M, Kaczmarek L. MMP-9 inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol. 2014;49(1):563–573.
   PubMed Web of Science ®Google Scholar
• Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke. 2012;43(12):3161–3167.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Watanabe M, Nagai Y, et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke. 2002;33(6):1493–1496.
   PubMed Web of Science ®Google Scholar
• Naito M. Effects of fibrinogen, fibrin and their degradation products on the behaviour of vascular smooth muscle cells. Nihon Ronen Igakkai Zasshi. 2000;37(6):458–463.
   PubMedGoogle Scholar